Immunotoxicity of Perfluorooctanoic Acid and Perfluorooctane Sulfonate and the Role of Peroxisome Proliferator-Activated Receptor Alpha

REFERENCES

• L.B. Biegel, M.E. Hurtt, S.R. Frame, J.C. O'Connor, and J.C. Cook. (2001). Mechanisms of extrahepatic tumor induction by peroxisome proliferators in male CD rats.. Toxicol Sci 60:44–55.
   PubMed Web of Science ®Google Scholar
• W.L. Blok, M.B. Katan, and J. van der Meer. (1996). Modulation of inflammation and cytokine production by dietary (n-3) fatty acids. J. Nutr 126:1515–1533.
   PubMed Web of Science ®Google Scholar
• J. Butenhoff, G. Costa, C. Elcombe, D. Farrar, K. Hansen, H. Iwai, R. Jung, G. KennedyJr., P. Lieder, G. Olsen, and P. Thomford. (2002). Toxicity of ammonium perfluorooctanoate in male cynomolgus monkeys after oral dosing for 6 months. Toxicol. Sci. 69:244–257.
   PubMed Web of Science ®Google Scholar
• J.L. Butenhoff, D.W. Gaylor, J.A. Moore, G.W. Olsen, J. Rodricks, J.H. Mandel, and L.R. Zubel. (2004). Characterization of risk for general population exposure to perfluorooctanoate. Regul. Toxicol. Pharmacol 39:363–380.
   PubMed Web of Science ®Google Scholar
• A.M. Calafat, L.L. Needham, Z. Kuklenyik, J.A. Reidy, J.S. Tully, M. Aguilar-Villalobos, and L.P. Naeher. (2006). Perfluorinated chemicals in selected residents of the American continent. Chemosphere 63:490–496.
   PubMed Web of Science ®Google Scholar
• L Canesi, L.C. Lorusso, C. Ciacci, M. Betti, F. Regoli, G. Poiana, G. Gallo, and A. Marcomini. (2007). Effects of blood lipid lowering pharmaceuticals (benzafibrate and gemfibrozil) on immune and digestive gland functions of the bivalve mollusc Mytilus galloprovincialis. Chemisophere 69:994–1002.
   PubMedGoogle Scholar
• M.T. Case, R.G. York, and M.S. Christian. (2001). Rat and rabbit oral developmental toxicology studies with two perfluorinated compounds. Int. J. Toxicol 20:101–109.
   PubMed Web of Science ®Google Scholar
• T. Chengyu, A. Ting, and B. Seed. (1998). PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82–86.
   PubMedGoogle Scholar
• G. Chinetti, S. Griglio, M. Antonicci, I.P. Torra, P. Delerive, Z. Majd, J.C. Fruchart, J. Chapman, J. Najib, and B. Stales. (1998). Activation of proliferation-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J. Biol. Chem. 273:25573–25580.
   PubMed Web of Science ®Google Scholar
• J.C. Cook, G.R. Klinefelter, J.F. Hardisty, R.M. Sharpe, and P.M. Foster. (1999). Rodent Leydig cell tumorigenesis: A review of the physiology, pathology, mechanisms, and relevance to humans. Crit. Rev. Toxicol. 29:169–261.
   PubMed Web of Science ®Google Scholar
• R. Cunard. (2005). The potential use of PPARalpha agonists as immunosuppressive agents. Curr. Opin. Invest. Drugs 6:467–472.
   PubMedGoogle Scholar
• R. Cunard, D. DiCampli, D.C. Archer, J.L. Stevenson, M. Ricote, C.K. Glass, and C.J. Kelly. (2002). WY14,643, a PPAR alpha ligand, has profound effects on immune responses in vivo. J. Immunol 169:6806–6812.
   PubMed Web of Science ®Google Scholar
• P. Delerive, K. De Bosscher, S. Besnard, W. vanden Berghe, J.M. Peters, F.J. Gonzalez, J.C. Fruchart, A. Tedgui, G. Haegeman, and B.J. Staels. (1999). Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J. Biol. Chem. 274:32048–32054.
   PubMed Web of Science ®Google Scholar
• P. Delerive, P. Gervois, J.-C. Fruchart, and B. Staels. (2000). Induction of IkBalpha expression as a mechanism contributing to the anti-inflammatory activities of PPAR-alpha activators. J. Biol. Chem. 275:36703–36707.
   PubMed Web of Science ®Google Scholar
• D. Deplanque, P. Gele, O. Pétrault, I. Six, C. Furman, M. Bouly, S. Nion, B. Dupuis, D. Leys, J.-C. Fruchart, R. Cecchelli, B. Staels, P. Duriez, and R. Bordet. (2003). Peroxisome proliferator-activates receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J. Neurosci 23:6264–6271.
   PubMed Web of Science ®Google Scholar
• P.R. Devchand, H. Keller, J.M. Peters, M. Vazquez, F.J. Gonzalez, and W. Wahli. (1996). The PPARalpha-leukotriene B4 pathway to inflammation and control. Nature 384:39–43.
   PubMed Web of Science ®Google Scholar
• J.C. DeWitt, C.B. Copeland, M.J. Strynar, and R.W. Luebke. (2008). Perfluorooctanoic acid-induced immunomodulation in adult C57BL/6J or C57BL/6N female mice. Environ. Health Perspect 116:644–650.
   PubMed Web of Science ®Google Scholar
• K. Du, S. Herzig, R.N. Kulkarni, and M. Montminy. (2003). TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science 300:1574–1577.
   PubMed Web of Science ®Google Scholar
• E.A. Emmett, F.S. Shofer, H. Zhang, D. Freeman, C. Desai, and L.M. Shaw. (2006). Community exposure to perfluorooctanoate: Relationships between serum concentrations and exposure sources. J. Occup. Environ. Med 48:759–770.
   PubMed Web of Science ®Google Scholar
• K.J. Fairley, R. Purdy, S. Kearns, S.E. Anderson, and B.J. Meade. (2007). Exposure to the immunosuppressant, perfluorooctanoic acid, enhances the murine IgE and airway hyperreactivity response to ovalbumin. Toxicol. Sci. 97:375–383.
   PubMed Web of Science ®Google Scholar
• J. Falandysz, S. Taniyasu, A. Gulkowska, N. Yamashita, and U. Schulte-Oehlmann. (2006). Is fish a major source of fluorinated surfactants and repellents in humans living on the Baltic Coast?. Environ. Sci. Technol 40:748–751.
   PubMed Web of Science ®Google Scholar
• F. Gagné, C. Blaise, M. Fournier, and P.D. Hansen. (2006). Effects of selected pharmaceutical products on phagocytic activity in Elliptio complanata mussels. Comp. Biochem. Physiol. C Toxicol. Pharmacol 143:179–186.
   PubMed Web of Science ®Google Scholar
• R.C. Grasty, D.C. Wolf, B.E. Grey, C.S. Lau, and J.M. Rogers. (2003). Prenatal window of susceptibility to perfluorooctane sulfonate-induced neonatal mortality in the Sprague-Dawley rat. Birth Defects Res 68:465–471.
   Google Scholar
• F.D. Griffith, and J.E. Long. (1980). Animal toxicity studies with ammonium perfluorooctanoate. Am. Ind. Hyg. Assoc. J 41:576–583.
   PubMed Web of Science ®Google Scholar
• J. Grosshans, and E. Wieschaus. (2000). A genetic link between morphogenesis and cell division during formation of the ventral furrow in Drosophila. Cell 101:523–531.
   PubMed Web of Science ®Google Scholar
• M.R. Grossman, M.E. Mispagel, and J.M. Bowen. (1992). Distribution and tissue elimination in rats during and after prolonged dietary exposure to a highly fluorinated sulfonamide pesticide. J. Agric. Food Chem 40:2505–2509.
   Web of Science ®Google Scholar
• K.S. Guruge, L.W.Y. Yeung, N. Yamanaka, S. Miyazaki, P.K.S. Lam, J.P. Giesy, P.D. Jones, and N. Yamashita. (2006). Gene expression profiles in rat liver treated with perfluorooctanoic acid (PFOA). Toxicol. Sci. 89:93–107.
   PubMed Web of Science ®Google Scholar
• M.R. Hill, S. Clarke, K. Roger, B. Thornhill, J.M. Peters, F.J. Gonzalez, and J.M. Gimble. (1999). Effect of peroxisome proliferators-activated receptor alpha activators on tumor necrosis factor expression in mice during endotoxemia. Infect. Immun 67:3488–3493.
   PubMed Web of Science ®Google Scholar
• M. Houde, R.S. Wells, P.A. Fair, G.D. Bossart, A.A. Hohn, T.K. Rowles, J.C. Sweeney, K.R. Solomon, and D.C.G. Muir. (2005). Polyfluoroalkyl compounds in free-ranging bottlenose dolphins (Tursiops truncates) from the Gulf of Mexico and the Atlantic Ocean. Environ. Sci. Technol 39:6591–6598.
   PubMed Web of Science ®Google Scholar
• International Research and Development Corporation. (1978). Ninety day subacute rat toxicity study. U.S. Environmental Protection Agency Administrative Record 226-0441. Washington, DC: IRDC.
   Google Scholar
• N.K. Jerne, and A.A. Nordin. (1963). Plaque formation in agar by single antibody-producing cells. Science 140:405.
   Web of Science ®Google Scholar
• J.D. Johnson, S.J. Gibson, and R.E. Ober. (1984). Cholestyramine-enhanced fecal elimination of carbon-14 in rats after administration of ammonium [14C]perfluorooctanoate or potassium [14C]perfluorooctanesulfonate. Fundam. Appl. Toxicol 4:972–976.
   PubMedGoogle Scholar
• L.A. Johnston. (2000). The trouble with tribbles. Curr. Biol 10:R502–504.
   Google Scholar
• D.C. Jones, B.M. Manning, and R.A. Daynes. (2002). A role for the peroxisome proliferator-activated receptor alpha in T-cell physiology and ageing immunobiology. Proc. Nutr. Soc 61:363–369.
   PubMedGoogle Scholar
• Y. Kamijo, K. Hora, T. Nakajima, K. Kono, K. Takahashi, Y. Ito, M. Higuchi, K. Kiyosawa, H. Shigematsu, F.J. Gonzalez, and T. Aoyama. (2007). Peroxisome proliferator-activated receptor alpha protects against glomerulonephritis induced by long-term exposure to the plasticizer di-(2-ethylhexyl)phthalate. J. Am. Soc. Nephrol 18:176–188.
   PubMedGoogle Scholar
• K. Kannan, L. Tao, E. Sinclair, S.D. Pastva, D.J. Jude, and J.P. Giesy. (2005). Perfluorinated compounds in aquatic organisms at various trophic levels in a Great Lakes food chain. Arch. Environ. Contam. Toxicol 48:559–566.
   PubMed Web of Science ®Google Scholar
• S. Kato, and K. Du. (2007). TRB3 modulates C2C12 differentiation by interfering with Akt activation. Biochem. Biophys. Res. Commun 353:933–938.
   PubMed Web of Science ®Google Scholar
• D.E. Keil, T. Mehlmann, L. Butterworth, and M.M. Peden-Adams. (2008). Gestational exposure to perfluorooctane sulfonate (PFOS) suppresses immune function in B6C3F1 mice. Toxicol. Sci. 103:77–85.
   PubMed Web of Science ®Google Scholar
• G.L. Kennedy, J.L. Butenhoff, G.W. Olsen, J.C. O'Connor, A.M. Seacat, R.G. Perkins, L.B. Biegel, S.R. Murphy, and D.G. Farrar. (2004). The toxicology of perfluorooctanoate. Crit. Rev. Toxicol. 34:351–384.
   PubMed Web of Science ®Google Scholar
• W. Klöpffer. (1994). Environmental hazard, assessment of chemicals and products. II. Persistence and dependability of organic chemicals. Environ. Sci. Pollut Res 1:108–116.
   PubMedGoogle Scholar
• H.J. Koh, D.E. Arnolds, N. Fujii, T.T. Tran, M.J. Rogers, N. Jessen, Y. Li, C.W. Liew, R.C. Ho, M.F. Hirshman, R.N. Kulkarni, C.R. Kahn, and L.J. Goodyear. (2006). Skeletal muscle-selective knockout of LKB1 increases insulin sensitivity, improves glucose homeostasis, and decreases TRB3. Mol. Cell Biol 26:8217–8227.
   PubMedGoogle Scholar
• S.H. Koo, H. Satoh, S. Herzig, C.H. Lee, S. Hedrick, R. Kulkarni, R.M. Evans, J. Olefsky, and M. Montminy. (2004). PGC-1 promotes insulin resistance in liver through PPAR-alpha-dependent induction of TRB-3. Nat. Med 10:530–534.
   PubMed Web of Science ®Google Scholar
• R. Kostadinova, W. Wahli, and L. Michalik. (2005). PPARs in diseases: Control mechanisms of inflammation. Curr Med Chem 12:2995–3009.
   PubMed Web of Science ®Google Scholar
• N. Kudo, E. Suzuki-Nakajima, A. Mitsumoto, and Y. Kawashima. (2006). Responses of the liver to perfluorinated fatty acids with different carbon chain length in male and female mice: In relation to induction of hepatomegaly, peroxisomal beta-oxidation and microsomal 1-acylglycerophosphocholine acyltransferase. Biol. Pharm. Bull 29:1952–1957.
   PubMed Web of Science ®Google Scholar
• C. Lau, J.R. Thibodeaux, R.G. Hanson, J.M. Rogers, B.E. Grey, M.E. Stanton, J.L. Butenhoff, and L.A. Stevenson. (2003). Exposure to perfluorooctane sulfonate during pregnancy in rat and mouse. II. Postnatal evaluation. Toxicol. Sci. 74:382–392.
   PubMed Web of Science ®Google Scholar
• C. Lau, J.R. Thibodeaux, R.G. Hanson, M.G. Narotsky, J.M. Rogers, A. Linstrom, and M.J. Strynar. (2006). Effects of perfluorooctanoic acid exposure during pregnancy in the mouse. Toxicol. Sci. 90:510–518.
   PubMed Web of Science ®Google Scholar
• S.E. Loveless, D. Hoban, G. Sykes, S.R. Frame, and N.E. Everds. Evaluation of the immune system in rats and mice administered linear ammonium perfluorooctanoate (APF). Toxicol. Sci. 105:86–96.
   PubMedGoogle Scholar
• A.E. Lovett-Racke, R.Z. Hussain, S. Northrup, J. Choy, A. Rocchini, L. Mathes, J.A. Chavis, A. Diab, P.D. Drew, and M.K. Racke. (2004). Peroxisome proliferators-activated receptor alpha agonists as therapy for autoimmune disease. J. Immunol 172:5790–5798.
   PubMed Web of Science ®Google Scholar
• D.J. Luebker, M.T. Case, R.G. York, J.A. Moore, K.J. Hansen, and J.L. Butenhoff. (2005a). Two-generation reproduction and cross-foster studies of perfluorooctanesulfonate (PFOS) in rats. Toxicology 215:126–148.
   PubMed Web of Science ®Google Scholar
• D.J. Luebker, R.G. York, K.J. Hansen, J.A. Moore, and J.L. Butenhoff. (2005b). Neonatal mortality from in utero exposure to perfluorooctanesulfonate (PFOS) in Sprague-Dawley rats: Dose-response, and biochemical and pharmacokinetic parameters. Toxicology 215:149–169.
   PubMed Web of Science ®Google Scholar
• A. Madej, B. Okopien, J. Kowalski, M. Zielinski, J. Wysocki, B. Szyhula, Z. Kalina, and Z.S. Herman. (1998). Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. Int. J. Clin. Pharmacol. Ther 36:345–351.
   PubMed Web of Science ®Google Scholar
• E. Maloney, and D. Waxman. (1999). trans-Activation of PPARalpha and PPARgamma by structurally diverse environmental chemicals. Toxicol. Appl. Pharmacol 161:209–218.
   PubMed Web of Science ®Google Scholar
• R.O. Manning, J.V. Bruckner, M.E. Mispagel, and J.M. Bowen. (1991). Metabolism and disposition of sulfluramid, a unique polyfluorinated insecticide, in the rat. Drug Metab. Dispos 19:205–211.
   PubMed Web of Science ®Google Scholar
• A. Mantovani, P. Allavena, and A. Sica. (2004). Tumour-associated macrophages as a prototypic type II polarised phagocyte population: Role in tumour progression. Eur. J. Cancer 40:1660–1667.
   PubMed Web of Science ®Google Scholar
• S. Maruyama, K. Kato, M. Kodama, S. Hirono, K. Fuse, O. Nakagawa, M. Nakazawa, T. Mida, T. Yamamoto, K. Watanabe, and Y. Aizawa. (2002). Fenofibrate, a peroxisome proliferator-activated receptor alpha activator, suppresses experimental autoimmune myocarditis by stimulating interleukin 10 pathway in rats. J. Atheroscler. Thromb 9:87–92.
   PubMedGoogle Scholar
• N. Marx, B. Kehrle, K. Kohlhammer, M. Grüb, W. Koenig, V. Hombach, P. Libby, and J. Plutzky. (2002). PPAR activators as anti-inflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ. Res 90:703–710.
   PubMed Web of Science ®Google Scholar
• J. Mata, S. Curado, A. Ephrussi, and P. Rorth. (2000). Tribbles coordinates mitosis and morphogenesis in Drosophila by regulating string/CDC25 proteolysis. Cell 101:511–522.
   PubMed Web of Science ®Google Scholar
• M. Matsumoto, S. Han, T. Kitamura, and D. Accili. (2006). Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. J. Clin. Invest 116:2464–2472.
   PubMed Web of Science ®Google Scholar
• R. Matsushima, N. Harada, N.J. Webster, Y.M. Tsutsumi, and Y. Nakaya. (2006). Effect of TRB3 on insulin and nutrient-stimulated hepatic p70 S6 kinase activity. J. Biol. Chem. 281:29719–29729.
   PubMed Web of Science ®Google Scholar
• R.I. Mishell, and R.W. Dutton. (1967). Immunization of dissociated spleen cell cultures from normal mice. J. Exp. Med 126:423–442.
   PubMed Web of Science ®Google Scholar
• M.A. M. Mollenhauer, J.A. Cook, P.A. Fair, and M.M. Peden-Adams. (2008). The effects of perfluorooctane sulfonate (PFOS) exposure on inflammation in B6C3F1 mice. Toxicologist CD 102 (S-1):40.
   Google Scholar
• D.M. Mosser. (2003). The many faces of macrophage activation. J. Leukocyte Biol 73:209–212.
   PubMed Web of Science ®Google Scholar
• T. Murai, T. Yamad, T. Miida, K. Arai, N. Endo, and T. Hnyu. (2002). Fenofibrate inhibits reactive amyloidois. Arthr Rheum 46:1683–1688.
   PubMedGoogle Scholar
• M.J. Palazzolo. (1993). Thirteen-week dietary toxicity study with T-5180, ammonium perfluorooctanoate (CAS No. 3825-26-1) in male rats. Final report. Laboratory Project Identification HW 6329-100. HazletonWisconsin, Inc. U.S. Environmental Protection Agency Administrative Record, AR 226-0449.
   Google Scholar
• M.M. Peden-Adams, J.G. EuDaly, S. Dabra, A. EuDaly, L. Heesemann, J. Smythe, and D.E. Keil. (2007). Suppression of humoral immunity following exposure to the perfluorinated insecticide sulfluramid. J. Toxicol. Environ. Health A 70:1130–1141.
   PubMed Web of Science ®Google Scholar
• M.M. Peden-Adams, J.M. Keller, J.G. EuDaly, J. Berger, G.S. Gilkeson, and D.E. Keil. (2008a). Suppression of humoral immunity in mice following exposure to perfluorooctane sulfonate (PFOS). Toxicol. Sci. doi: 10.1093/toxsci/kfn059.
   Google Scholar
• M.M. Peden-Adams, M.A.M. Mollenhauer, E. Driscoll, S.G. Bradshaw, J. Berger, P.A. Fair, and D.E. Keil. (2008b). Evaluation of possible modes of action for PFOS-induced humoral immunosuppression. Toxicologist CD 102 (S-1):34.
   Google Scholar
• M.E. Poynter, and T.A. Daynes. (1998). Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappa B signaling, and reduces inflammatory cytokine production in aging. J. Biol. Chem. 273:32833–32841.
   PubMed Web of Science ®Google Scholar
• S.B. Pruett, S. Collier, W.J. Wu, and R. Fan. (1999). Quantitative relationships between the suppression of selected immunological parameters and the area under the corticosterone concentration vs. time curve in B6C3F1 mice subjected to exogenous corticosterone or to restraint stress. Toxicol. Sci. 49:272–280.
   PubMed Web of Science ®Google Scholar
• S.B. Pruett, P. Hebert, J. Lapointe, M.L. Reagan, and T.T. Kawabata. (2007). Characterization of the action of drug-induced stress responses on the immune system: Evaluations of biomarkers for drug-induced stress in rats. J. Immunotoxicol 4:25–38.
   PubMed Web of Science ®Google Scholar
• L. Qi, J.E. Heredia, J.Y. Altarejos, R. Screaton, N. Goebel, S. Niessen, I.X. Macleod, C.W. Liew, R.N. Kulkarni, J. Bain, C. Newgard, M. Nelson, R.M. Evans, J. Yates, and M. Montminy. (2006). TRB3 links the E3 ubiquitin ligase COP1 to lipid metabolism. Science 312:1763–1766.
   PubMed Web of Science ®Google Scholar
• M. Ricote, A.C. Li, T.M. Willson, C.J. Kelley, and C.K. Glass. (1998). The peroxisome proliferators-activated receptor gamma is a negative regulator of macrophage activation. Nature 391:79–82.
   PubMed Web of Science ®Google Scholar
• Riker Laboratories. (1987). Two year oral (diet) toxicity/carcinogenicity study of FC-143 in rats. U.S. Environmental Protection Agency Administrative Records 226-0437, 226-0438, 226-0439, and 226-440.
   Google Scholar
• A.R. Saltiel. (2003). Putting the brakes on insulin signaling. N. Engl. J. Med 349:2560–2562.
   PubMed Web of Science ®Google Scholar
• A.M. Seacat, and D.J. Luebker. (2000). Toxicokinetic study of perfluorooctane sulfonamide (PFOSA;T-7132.2) in rats. Available on U.S. Environmental Protection Agency Public Docket AR-226 (No. 226-0993).
   Google Scholar
• A.M. Seacat, P.J. Thomford, K.J. Hansen, L.A. Clemen, S.R. Eldridge, C.R. Elcombe, and J.L. Butenhoff. (2003). Sub-chronic dietary toxicity of potassium perfluorooctanesulfonate in rats. Toxicology 183:117–131.
   PubMed Web of Science ®Google Scholar
• T.C. Seher, and M. Leptin. (2000). Tribbles, a cell-cycle brake that coordinates proliferation and morphogenesis during Drosophila gastrulation. Curr. Biol 10:623–629.
   PubMedGoogle Scholar
• E. Selim, J.T. Frkanec, and R. Cunard. (2007). Fibrates upregulate TRB3 in lymphocytes independent of PPARalpha by augmenting CCAAT/enhancer-binding proteinbeta (C/EBPbeta) expression. Mol. Immunol 44:1218–1229.
   PubMedGoogle Scholar
• B. Staels, W. Koenig, A. Habib, R. Merval, M. Lebret, I.P. Torra, P. Delerive, A. Fadel, G. Chinetti, J.C. Fruchart, J. Najib, J. Maclouf, and A. Tedgui. (1998). Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 303:790–793.
   Google Scholar
• C.G. Su, X. Wen, S.T. Bailey, W. Jiang, S.M. Rangwala, S.A. Kielbaugh, A. Flanigan, S. Murthy, M.A. Lazar, and G.G. Wu. (1999). A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J. Clin. Invest 104:383–389.
   PubMed Web of Science ®Google Scholar
• T. Tanaka, H. Kohno, S. Yoshitani, S. Takashima, A. Okumura, A. Murakami, and M. Hosokawa. (2001). Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res 61:2424–2428.
   PubMed Web of Science ®Google Scholar
• B.K. Taylor, N. Dadia, C.B. Yank, C. Kriedt, S. Krisnan, and M. Badr. (2002). Peroxisome proliferator-activated receptor agonists inhibit inflammatory edema and hyperalgesia. Inflammation 26:121–127.
   PubMed Web of Science ®Google Scholar
• B.K. Taylor, C. Kriedt, S. Nagalingham, N. Dadia, and M. Badr. (2005). Central administration of perfluorooctanoic acid inhibits cutaneous inflammation. Inflamm. Res 54:235–242.
   PubMed Web of Science ®Google Scholar
• J.R. Thibodeaux, R.G. Hanson, J.M. Rogers, B.E. Grey, B.D. Barbee, J.H. Richards, J.L. Butenhoff, L.A. Stevenson, and C. Lau. (2003). Exposure to perfluorooctane sulfonate during pregnancy in rat and mouse. I. Maternal and prenatal evaluations. Toxicol. Sci. 74:369–381.
   PubMed Web of Science ®Google Scholar
• A. Trifilieff, A. Bench, M. Hanley, D. Bayley, E. Campbell, and P. Whittaker. (2003). PPAR-alpha and -gamma but not -delta agonists inhibit airway inflammation in a murine model of asthma: In vitro evidence for an NF-kappaB-independent effect. Br. J. Pharmacol 139:163–171.
   PubMedGoogle Scholar
• U.S. Environmental Protection Agency. (2002). Revised draft. Hazard assessment of perfluorooctanoic acid and its salts. U.S. Environmental Protection Agency Public Docket AR-226.
   Google Scholar
• J.P. Vanden Heuvel. (2007). The PPAR resource page. Biochim Biophys Acta 1771:1108–1112.
   PubMedGoogle Scholar
• J.P. Vanden Heuvel, J.T. Thompson, S.R. Frame, and P.J. Gillies. (2006). Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: A comparison of human, mouse, and rat peroxisome proliferator-activated receptor-alpha, -beta, and -gamma, liver X receptor-beta, and retinoid X receptor-alpha. Toxicol. Sci. 92:476–489.
   PubMed Web of Science ®Google Scholar
• P.O. Villanueva, T.S. Harris, D.E. Ricklan, and M.J. Stadecker. (1994). Macrophages from schistosomal egg granulomas induce unresponsiveness in specific cloned Th-1 lymphocytes in vitro and down-regulate schistosomal granulomatous disease in vivo. J. Immunol 152:1847–1855.
   PubMedGoogle Scholar
• T.J. Wams. (1987). Diethylhexylphthalate as an environmental contaminant—A review. Sci. Total Environ 66:1–16.
   PubMed Web of Science ®Google Scholar
• Y.J. Wan, and M.Z. Badr. (2006). Inhibition of carregeenan-induced cutaneous inflammation by PPAR agonists is dependent on hepatocyte-specific retinoid X receptor alpha. PPAR Res 2006:1–6.
   Google Scholar
• J. Whelan. (1996). Antagonistic effects of dietary arachidonic acid and n-3 polyunsaturated fatty acids. J. Nutr 126:1086S–1091S.
   PubMed Web of Science ®Google Scholar
• S.S. White, A.M. Calafat, Z. Kuklenyik, L. Villanueva, R.D. Zehr, L. Helfant, M.J. Strynar, A.B. Lindstrom, J.R. Thibodeaux, C. Wood, and S.E. Fenton. (2007). Gestational PFOA exposure of mice is associated with altered mammary gland development in dams and female offspring. Toxicol. Sci. 96:133–144.
   PubMed Web of Science ®Google Scholar
• T.M. Willson, P.J. Brown, D.D. Sternbach, and B.R. Henke. (2000). The PPARs: From orphan receptors to drug discovery. J. Med. Chem 43:527–550.
   PubMed Web of Science ®Google Scholar
• C.J. Wolf, S.E. Fenton, J.E. Schmid, A.M. Calafat, Z. Kuklenyik, X.A. Bryant, J.R. Thibodeaux, K.P. Das, S.S. White, C.S. Lau, and B.D. Abbott. (2007). Developmental toxicity of perfluorooctanoic acid in the CD-1 mouse after cross-foster and restricted gestational exposure. Toxicol. Sci. 95:462–473.
   PubMed Web of Science ®Google Scholar
• Q.W. Xie, Y. Kashiwabara, and C. Nathan. (1994). Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J. Biol. Chem. 269:4705–4708.
   PubMed Web of Science ®Google Scholar
• Q. Yang, M. Abedi-Valugerdi, Y. Xie, X.Y. Zhao, G. Moller, B.D. Nelson, and J.W. DePierre. (2002a). Potent suppression of the adaptive immune response in mice upon dietary exposure to the potent peroxisome proliferator, perfluorooctanoic acid. Int. Immunopharmacol 2:389–397.
   PubMed Web of Science ®Google Scholar
• Q. Yang, Y. Xie, S.E. Alexson, B.D. Nelson, and J.W. DePierre. (2002b). Involvement of the peroxisome proliferator-activated receptor alpha in the immunomodulation caused by peroxisome proliferators in mice. Biochem. Pharmacol 63:1893–1900.
   PubMed Web of Science ®Google Scholar
• Q. Yang, Y. Xie, and J.W. Depierre. (2000). Effects of peroxisome proliferators on the thymus and spleen of mice. Clin. Exp. Immunol 122:219–226.
   PubMed Web of Science ®Google Scholar
• Q. Yang, Y. Xie, A.M. Eriksson, B.D. Nelson, and J.W. DePierre. (2001). Further evidence for the involvement of inhibition of cell proliferation and development in thymic and splenic atrophy induced by the peroxisome proliferator perfluoroctanoic acid in mice. Biochem. Pharmacol 62:1133–1140.
   PubMed Web of Science ®Google Scholar
• J. Yao, N. Mackman, T.S. Edgington, and S.T. Fan. (1997). Lipopolysaccharide induction of the tumor necrosis factor-alpha promoter in human monocytic cells. Regulation by Egr-1, c-Jun, and NF-kappaB transcription factors. J. Biol. Chem. 272:17795–17801.
   PubMed Web of Science ®Google Scholar